GSA Capital Partners LLP Has $1.13 Million Holdings in Frequency Therapeutics, Inc. (NASDAQ:FREQ)

GSA Capital Partners LLP boosted its position in Frequency Therapeutics, Inc. (NASDAQ:FREQGet Rating) by 169.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 219,932 shares of the company’s stock after acquiring an additional 138,280 shares during the quarter. GSA Capital Partners LLP’s holdings in Frequency Therapeutics were worth $1,128,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of FREQ. Citigroup Inc. grew its position in Frequency Therapeutics by 56.6% in the 4th quarter. Citigroup Inc. now owns 9,203 shares of the company’s stock worth $47,000 after purchasing an additional 3,325 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Frequency Therapeutics in the 4th quarter worth $69,000. Franklin Resources Inc. acquired a new stake in Frequency Therapeutics in the 3rd quarter worth $73,000. Invesco Ltd. acquired a new stake in Frequency Therapeutics in the 2nd quarter worth $121,000. Finally, SG Americas Securities LLC acquired a new stake in Frequency Therapeutics in the 3rd quarter worth $154,000. Institutional investors and hedge funds own 50.64% of the company’s stock.

Several research firms have issued reports on FREQ. Zacks Investment Research lowered shares of Frequency Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. B. Riley decreased their target price on shares of Frequency Therapeutics from $17.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, March 23rd.

Shares of Frequency Therapeutics stock traded up $0.06 during trading on Wednesday, hitting $1.17. 1,410 shares of the company’s stock traded hands, compared to its average volume of 551,517. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.85 and a quick ratio of 9.85. The firm’s fifty day moving average price is $1.66 and its 200 day moving average price is $3.69. Frequency Therapeutics, Inc. has a twelve month low of $1.07 and a twelve month high of $10.90. The company has a market cap of $40.75 million, a PE ratio of -0.44 and a beta of 0.96.

Frequency Therapeutics (NASDAQ:FREQGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.01). As a group, equities research analysts anticipate that Frequency Therapeutics, Inc. will post -2.44 earnings per share for the current year.

Frequency Therapeutics Profile (Get Rating)

Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.

See Also

Want to see what other hedge funds are holding FREQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Frequency Therapeutics, Inc. (NASDAQ:FREQGet Rating).

Institutional Ownership by Quarter for Frequency Therapeutics (NASDAQ:FREQ)

Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.